<DOC>
	<DOCNO>NCT02556229</DOCNO>
	<brief_summary>Inflammatory choroidal neovascularization ( InCNV ) third cause CNV myopia Age-related Macular Degeneration ( AMD ) . InCNV rare severe disease treatment delay . InCNV treat moment off-label anti-VEGF ( Vascular Endothelial Growth Factor ) therapy could also benefit aflibercept ( EYLEA ) , new anti-VEGF currently indicate AMD . Case report suggest patient would need many injection AMD . ALINEA open-label , single arm , prospective , multicenter , phase II study . The main objective demonstrate effectiveness clinical term 52 week treatment aflibercept visual acuity patient affect InCNV . A specific dosage regimen design achieve maximum efficiency . The patient follow monthly basis 52 week . The first injection mandatory . The one inject case active InCNV .</brief_summary>
	<brief_title>Study Evaluating Efficacy Aflibercept Treatment Inflammatory CNV Young Patients ( ALINEA ) .</brief_title>
	<detailed_description />
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<criteria>18 &lt; Age &lt; 50 year old Patient give voluntary sign informed consent Patient affiliate French universal health care system similar Patient inflammatory CNV , whatever cause , include multifocal choroiditis , punctate inner choroidopathy , ocular toxoplasmosis , serpiginous choroiditis Birdshot chorioretinopathy active primary subfoveal , retrofoveal juxtafoveal lesion affect fovea evidence angiography ( fluorescein and/or indocyanine green ) and/or SDOCT study eye Patient willing , committed able return clinic visit complete studyrelated procedure Pregnant woman Sexually active men woman childbearing potential unwilling practice adequate contraception study Patient protect adult accord term law ( French public health law ) Involvement another clinical trial ( study eye and/or eye ) Patient noninflammatory CNV , especially : AMD High myopia define refraction ≥ 6 diopter Other curative treatment inflammatory CNV study eye last 3 month first intravitreal injection : antiVEGF therapy , juxta extrafoveal macular laser , photodynamic therapy , surgery , external radiotherapy , transpupillary thermotherapy ... Medical history retrofoveal focal macular laser photocoagulation study eye Subretinal hemorrhage reach fovea center size &gt; 50 % lesion area Fibrosis retrofoveal retinal atrophy study eye Retinal pigment epithelial tear reach macula study eye Medical history intravitreal medical device study eye Medical history autoimmune idiopathic uveitis Proved diabetic retinopathy Intraocular pressure ≥ 25 mmHg despite two topical hypotonic treatment Aphakia lack lens capsule ( remove YAG ( yttrium aluminium garnet ) laser ) study eye Arterial hypertension control appropriate treatment define one measure systolic blood pressure &gt; 180mmHG 2 consecutive measure &gt; 160mmHg , diastolic blood pressure &gt; 100mmHg Antecedents cerebrovascular disease myocardial infarction last 6 month inclusion ( J1 ) Antecedents pathology , metabolic disease , serious suspicion disease clinical laboratory exam would contraindicate use product , could affect interpretation study result lead major risk complication subject Renal insufficiency require dialysis renal transplantation Previous ( less year ) actual treatment systemic administration antiVEGF therapy Known hypersensitivity aflibercept , another drug composite medicinal product use ; allergy fluorescein , indocyanine green , anaesthetic eye drop Active suspect ocular periocular infection Medical history intraocular surgery within 28 day first injection study eye Any illness ocular condition would require intraocular surgery study eye within 12 month inclusion Follow possible 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Aflibercept</keyword>
	<keyword>inflammatory choroidal neovascularization</keyword>
	<keyword>young patient</keyword>
</DOC>